Daniel Menichella is appointed CEO of CureVac Inc., CureVac AG’s Boston-based U.S. subsidiary. Menichella has held a variety of corporate and business development roles for a number of leading companies during his career, including Bamboo Therapeutics, Applied Genetic Technologies Corp., Zyngenia Inc., Talecris Biotherapeutics Holdings Corp., and Merck KGaA.
Theresa Podrebarac, M.D., has joined enGene as chief medical officer. Dr. Podrebarac came from AbbVie, where she served as VP, Immunology Clinical Development.
Brian Kotzin, M.D. is now head of clinical development for Nektar Therapeutics’ Immunology Program. In this newly created role, Dr. Kotzin is leading clinical development for NKTR-358, a first-in-class regulatory T cell stimulator, being developed for the treatment of immune and inflammatory disorders. Dr. Kotzin was previously at Amgen, where he served as VP, Global and Clinical Development and head, Inflammation Therapeutic Area.
Dr. Joanne Bedwell-Garner has become development director at Macrophage Pharma Limited. Prior to this appointment she held senior roles at Protherics, Emergent BioSolutions, and Microscience.
Robert Imani, M.D., Ph.D., has been appointed VP, drug development, at Tolero Pharmaceuticals. He was most recently executive medical director at Onyx Pharmaceuticals Inc. and Amgen Inc.
Daryl Drummond, Ph.D., has been appointed head of research at Merrimack Pharmaceuticals Inc. He was most recently VP of discovery and team leader for Merrimack’s early-stage pipeline.